UroGen reports Q4/FY2024: JELMYTO rev $90.4M; net loss $126.9M; guides FY2025 rev $94-98M

UroGen Pharma Ltd.

UGN-102 NDA under FDA review; PDUFA June 13, 2025; 18-month DOR 80.6% in Phase 3 ENVISION trial.
JELMYTO net product revenue $90.4M in FY2024, up 9% YoY; underlying demand revenue grew 12% (FY) and 15% (Q4).
Net loss Q4 2024 $37.5M ($0.80/share) vs $26.0M ($0.72/share) in Q4 2023; FY net loss $126.9M ($2.96/share) vs $102.2M ($3.55/share).
FY2025 guidance: JELMYTO revenue $94-98M; operating expenses $215-225M (incl. $11-14M share-based comp).
Cash, equivalents and marketable securities $241.7M at Dec 31, 2024, up from $141.5M at Dec 31, 2023.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.